Product Information
RIZATRIPTAN 5 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.3480 per EA under NDC 33342008745. Its NADAC has been published 382 times since Jun 12, 2019.
FDA first approved this application on Feb 11, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342008745
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIZATRIPTAN BENZOATEApproval Type
Generic (ANDA)
FDA Application
ANDA203147FDA Approved
2/11/2014
TE Code
AB
On Market Since
3/11/2014
Pharmacological Classes
Price Statistics
The NADAC for RIZATRIPTAN 5 MG TABLET has been published 382 times since Jun 12, 2019, and over the history we have for it it has declined 58.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3480 per EA |
|---|---|
| All-time high | $1.0277 (Jan 15, 2020) |
| All-time low | $0.3203 (Jul 17, 2024) |
| 52-week high | $0.5666 |
| 52-week low | $0.3446 |
| Median price | $0.5528 |
| Average price | $0.6033 |
| Largest weekly change | +74.4% (Aug 21, 2024) |
| Weeks tracked | 382 |
| Tracking since | Jun 12, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rizatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIZATRIPTAN 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RIZATRIPTAN 5 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.3480 per EA (NDC 33342008745), effective Sep 30, 2026.
How has the price of RIZATRIPTAN 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for RIZATRIPTAN 5 MG TABLET has declined 58.5%. It has been tracked across 382 weekly CMS publications since Jun 12, 2019.
What are the highest and lowest recorded NADAC prices for RIZATRIPTAN 5 MG TABLET?
Since Jun 12, 2019, the NADAC for RIZATRIPTAN 5 MG TABLET has ranged from a low of $0.3203 (Jul 17, 2024) to a high of $1.0277 (Jan 15, 2020), with a median of $0.5528 per EA.
Are there cheaper alternatives to RIZATRIPTAN 5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as RIZATRIPTAN 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RIZATRIPTAN 5 MG TABLET?
RIZATRIPTAN 5 MG TABLET (NDC 33342008745) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.